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We have examined the requirement for Ca21 in the
signaling and trafficking pathways involved in insulin-
stimulated glucose uptake in 3T3-L1 adipocytes. Chela-
tion of intracellular Ca21, using 1,2-bis (o-aminophe-
noxy)ethane-N,N,N*,N*-tetraacetic acid tetra (acetoxy-
methyl) ester (BAPTA-AM), resulted in >95% inhibition
of insulin-stimulated glucose uptake. The calmodulin
antagonist, W13, inhibited insulin-stimulated glucose
uptake by 60%. Both BAPTA-AM and W13 inhibited Akt
phosphorylation by 70–75%. However, analysis of insu-
lin-dose response curves indicated that this inhibition
was not sufficient to explain the effects of BAPTA-AM
and W13 on glucose uptake. BAPTA-AM inhibited insu-
lin-stimulated translocation of GLUT4 by 50%, as deter-
mined by plasma membrane lawn assay and subcellular
fractionation. In contrast, the insulin-stimulated ap-
pearance of HA-tagged GLUT4 at the cell surface, as
measured by surface binding, was blocked by BAPTA-
AM. While the ionophores A23187 or ionomycin pre-
vented the inhibition of Akt phosphorylation and
GLUT4 translocation by BAPTA-AM, they did not over-
come the inhibition of glucose transport. Moreover, glu-
cose uptake of cells pretreated with insulin followed by
rapid cooling to 4 °C, to promote cell surface expression
of GLUT4 and prevent subsequent endocytosis, was in-
hibited specifically by BAPTA-AM. This indicates that
inhibition of glucose uptake by BAPTA-AM is independ-
ent of both trafficking and signal transduction. These
data indicate that Ca21 is involved in at least two differ-
ent steps of the insulin-dependent recruitment of
GLUT4 to the plasma membrane. One involves the trans-
location step. The second involves the fusion of GLUT4
vesicles with the plasma membrane. These data are con-
sistent with the hypothesis that Ca21/calmodulin plays a
fundamental role in eukaryotic vesicle docking and fu-
sion. Finally, BAPTA-AM may inhibit the activity of the
facilitative transporters by binding directly to the trans-
porter itself.
Insulin stimulates glucose uptake in skeletal muscle and
adipose tissue by stimulating the translocation of a facilitative
glucose transporter, GLUT4, from an intracellular compart-
ment to the cell surface. In recent years considerable progress
has been made in our understanding of the downstream signal
transduction pathways that are activated by insulin to mediate
the translocation of GLUT4 to the cell surface. Upon insulin
binding, the activated insulin receptor (IR)1 tyrosine kinase
phosphorylates a number of downstream substrates, most no-
tably the insulin receptor substrate (IRS) family of proteins,
including IRS-1 and IRS-2 (1). Tyrosyl-phosphorylated IRS-1
and IRS-2 serve as docking stations for SH2 domain-containing
proteins such as the class Ia (p85/p110-type) PI 3-kinase (1).
Activation of PI 3-kinase is essential for insulin-stimulated
GLUT4 translocation and glucose uptake (2) with generation of
phosphoinositide 3,4,5-trisphosphate at the plasma membrane
(PM) (3) serving to recruit and activate pleckstrin homology
domain-containing proteins. Recent evidence indicates that the
pleckstrin homology domain-containing Ser/Thr kinase Akt
(otherwise called protein kinase B) plays a fundamental role in
mediating insulin-stimulated GLUT4 translocation (4–6).
A direct link between the insulin-signaling cascade and the
more distal events associated with GLUT4 trafficking is yet to
be identified. The precise nature of the insulin-responsive
GLUT4 storage vesicle (GSV) and a detailed molecular descrip-
tion of how insulin promotes translocation of the GSV to the
PM remain to be defined. In contrast, the mechanism by which
GSVs dock and fuse with the PM is better understood, in part
because of the similarity with synaptic vesicle trafficking in
neurons. Both of these events involve the pairing of protein
complexes in the vesicle compartment (v-SNARES, for vesicle
membrane SNAP receptors) with cognate receptor complexes
at the target membrane (t-SNARES, for target membrane
SNAP receptors). Interactions between v-SNARE and
t-SNARE proteins, as well as additional accessory proteins, are
responsible for formation of the core complex, which is required
for membrane docking and fusion (7). In adipocytes the core
complex is comprised of the v-SNARE, VAMP2, and the t-
SNAREs, syntaxin 4 and SNAP23 (8). In view of the similarity
in molecular regulation between GLUT4 translocation in adi-
pocytes and synaptic vesicle exocytosis in neurons, it has been
suggested that GLUT4 translocation may represent a form of
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regulated exocytosis. Most regulated exocytic processes share
several characteristic features. These include segregation of
the cargo to be transported, increased delivery of this cargo to
the cell surface in response to secretagogue, and the involve-
ment of Ca21 in the delivery process.
Although numerous studies have examined the role of Ca21
in insulin-stimulated glucose transport, there remains little
consensus concerning its overall role in this process. Investiga-
tions in L6 muscle cells, cardiac myocytes, and adipocytes
failed to find a clear link between Ca21 and glucose metabolism
(9–12). In contrast, reduction of intracellular Ca21 in rat
adipocytes markedly inhibited insulin-stimulated glucose
transport (13–15). Ca21 may play a permissive role, or it may
actively drive one or more of the steps involved in insulin-
stimulated GLUT4 trafficking. In the latter case insulin may
increase cytosolic Ca21 by regulating the activity of a Ca21
channel. In the former case there may be no change in cytosolic
Ca21 with insulin stimulation. Intuitively one might imagine
at least two loci where Ca21 might be involved in mediating the
effects of insulin on glucose uptake. Firstly, Ca21/calmodulin
has been implicated in mediating insulin activation of PI 3-ki-
nase and Akt in rat hepatocytes and in 3T3-L1 adipocytes (16,
17). Secondly, several recent studies have reported a key role
for Ca21/calmodulin in the late stages of vesicle docking/fusion
(18–21). Thus, Ca21 could be required both for the proximal
signaling events of the insulin cascade and/or in the final
stages of docking of GSVs with the plasma membrane.
In the present investigation we have re-evaluated the role of
Ca21 in insulin-stimulated glucose transport in 3T3-L1 adipo-
cytes. To do this we have employed the membrane permeable
form of the Ca21-chelating agent BAPTA-AM and the calmod-
ulin antagonist W13. BAPTA-AM and W13 reduced insulin-
stimulated glucose uptake by 95 and 60% and Akt phosphoryl-
ation by 75 and 70%, respectively. BAPTA-AM reduced GLUT4
translocation to the plasma membrane by 50% as determined
by subcellular fractionation analyses. However, by using an
antibody binding assay that measured insertion of glucose
transporters into the membrane, we observed almost 100%
inhibition of insulin-stimulated GLUT4 translocation in re-
sponse to BAPTA-AM. We also found that treatment with
ionophores prevented the inhibition of Akt phosphorylation
and GLUT4 translocation by BAPTA-AM. These data indicate
that Ca21/calmodulin is required for the efficient activation of
Akt and are consistent with an obligate role for Ca21 at a late
post-docking stage in GLUT4 vesicle fusion.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—All reagents were from Sigma unless spec-
ified otherwise. All tissue culture medium was purchased from Life
Technologies Inc., except fetal calf serum, which was obtained from
Trace Biosciences (Clayton, Australia). Bovine serum albumin was
purchased from ICN (Costa Mesa, CA). Insulin was obtained from
Calbiochem. The Ca21 chelators, BAPTA-AM, BAPTA, and EGTA-AM,
and ionophores, A23187 and ionomycin, were also from Calbiochem.
The calmodulin antagonist W13 was from Sigma. The polyclonal
GLUT4 and IRAP antibodies have been described previously (22, 23).
BCA reagent, used in protein assays, was from Pierce. The anti-phos-
photyrosine monoclonal antibody (4G10) was provided by Dr. B. Druker
(Oregon Health Sciences University, Portland, OR). Anti-IRS-1 poly-
clonal antibody was from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Anti-p85 and anti-IRS-2 polyclonal antibodies were from Upstate
Biotechnology Inc. (Lake Placid, NY). The monoclonal anti-influenza
hemagglutinin (HA) epitope antibody was from Babco (Richmond, CA).
Antiphospho-Ser473Akt antibody was from New England Biolabs (Bev-
erly, MA). Fluorescein isothiocyanate-conjugated secondary antibodies
were from Molecular Probes (Eugene, OR). Peroxidase-coupled second-
ary antibodies were from Amersham Pharmacia Biotech.
Cell Culture and Treatments—3T3-L1 fibroblasts were cultured and
differentiated into adipocytes as described previously (24). CHO cells
stably overexpressing the IR (CHO.IR cells) were cultured as described
previously (25). In all experiments cells were serum-starved in Krebs-
Ringer phosphate (KRP) buffer (12.5 mM HEPES, pH 7.4, 120 mM NaCl,
6 mM KCl, 1.2 mM MgSO4, 1 mM CaCl2, 0.4 mM NaH2PO4, 0.6 mM
Na2HPO4) supplemented with 0.2% bovine serum albumin (BSA) for at
least 2 h at 37 °C, and all further treatments were performed in the
same buffer except where insulin stimulation and 2-DOG uptake were
carried out in KRP buffer without Ca21. In these experiments cells were
rinsed in prewarmed KRP buffer as described above, except that it was
without CaCl2 and supplemented with 5 mM EGTA, and incubated in
this buffer for the duration of insulin stimulation and 2-DOG uptake.
Where indicated, cells were incubated with BAPTA-AM (50 mM, made
up in Me2SO) for 10 min followed by insulin (1 mM) for 15 min at 37 °C
in the continued presence of BAPTA-AM. Incubation of cells in KRP
with 0.2% BSA supplemented with 3 mM pyruvate gave comparable
results (data not shown). In other experiments, cells were incubated
with W13 (70 mM (17), made up in H2O) for 20 min followed by insulin
(1 mM) for 15 min at 37 °C in the continued presence of W13. In
experiments to investigate the effects of BAPTA-AM on glucose uptake
post-insulin treatment, cells were incubated with insulin (1 mM) for 15
min at 37 °C. Following this, cells were rapidly cooled to 4 °C by wash-
ing with ice-cold KRP and incubated in the same buffer on ice. The cells
were then incubated at 4 °C in the absence or the presence of BAPTA-
AM, BAPTA, or EGTA-AM (all at 50 mM) or W13 (70 mM) for the times
indicated, such that all cells were incubated at 4 °C for the same
duration. In experiments involving the ionophores, A23187 or ionomy-
cin (0.1 mM, made up in MeOH) was added simultaneously to the
addition of BAPTA-AM. Treatment of cells with vehicle alone or in
combination (at the appropriate final concentrations) was without effect
in control experiments (data not shown).
Cell Fractionation—Following incubation with the appropriate
agents, 3T3-L1 adipocytes were washed twice with ice-cold HES buffer
(20 mM HEPES, pH 7.4, 1 mM EDTA, 250 mM sucrose) and homogenized
in the same buffer supplemented with phosphatase and protease inhib-
itors (2 mM sodium orthovanadate, 10 mM sodium fluoride, 1 mM tetra-
sodium pyrophosphate, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 250 mM
phenylmethylsulfonyl fluoride). Subcellular fractions were isolated by
differential centrifugation as previously detailed (25) or by a modified
protocol that gave comparable results. The modified protocol differed
from that described (25) in the preparation of the PM fraction. In brief,
centrifugation at 2,000 3 g for 10 min was performed to remove mito-
chondria, nuclei, and unbroken cells. The resulting supernatant was
then centrifuged at 18,000 3 g for 20 min to pellet the crude PM
fraction. This pellet was resuspended in HES buffer containing inhib-
itors and centrifuged again at 2,000 3 g for 10 min to remove contam-
inating material. The supernatant from this was then centrifuged again
at 18,000 3 g for 20 min to pellet the PM fraction. The high speed pellet
(otherwise termed low density microsomal fraction) was prepared from
the supernatant from the first 18,000 3 g spin as described (25).
Immunoblotting and Densitometry Analysis—The protein content of
all samples was determined using BCA reagent. The samples (10 mg)
were subjected to SDS-PAGE and transferred to Immobilon-P polyvi-
nylidene difluoride membranes (Millipore Corporation, Bedford, MA),
and the membranes were probed with the appropriate primary and
horseradish peroxidase-conjugated secondary antibodies. Antibody
binding was detected by enhanced chemiluminescence according to the
manufacturer’s instructions (Supersignal, Pierce). The protein bands
were quantified by densitometry (GS-700 Imaging densitometer, Bio-
Rad) using nonsaturated exposed x-ray films.
Glucose Uptake Assays—2-Deoxy-[3H]glucose uptake was measured
as described previously (26). In brief, 3T3-L1 adipocytes in 12-well
plates were incubated in the absence or the presence of compounds, as
indicated, in 500 ml of KRP with 0.2% BSA. The assay was initiated by
adding 50 ml of 1 mM 2-deoxy-[3H]glucose (20 mCi/mmol)/KRP and
terminated after 1–2 min by washing cells rapidly three times with
ice-cold PBS. The cells were solubilized in 1% Triton X-100, and 3H was
quantitated by scintillation counting (Packard 1900CA liquid scintilla-
tion analyzer, Packard Instrument Co.). Glucose uptake was measured
in duplicate in all treatments. Nonspecific uptake of 2-deoxy-[3H]glu-
cose was determined by the addition of cytochalasin B (50 mM) to the
appropriate controls prior to the commencement of assays. Measure-
ment of the transport of the nonmetabolizable glucose analogue 3-O-
[methyl-3H]glucose was performed essentially as described above ex-
cept that the assay was terminated after 45 s by washing cells three
times in ice-cold PBS containing phloretin (100 mM).
Plasma Membrane Lawn Assay—The PM lawn assay was performed
essentially as described (27). In brief, 3T3-L1 adipocytes grown on glass
coverslips were treated as indicated and then sonicated using a probe
sonicator (Kontes Co., Vineland, NJ) to generate a lawn of PM frag-
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ments attached to the coverslip. The coverslips were then incubated in
GLUT4-specific antiserum, followed by incubation with fluorescein iso-
thiocyanate-conjugated secondary antibody. Coverslips were washed
with PBS, mounted onto glass microscope slides, and viewed using a
633/1.4 Zeiss oil immersion objective on a Zeiss Axiovert fluorescence
microscope equipped with a Bio-Rad MRC-600 laser confocal imaging
system. Duplicate coverslips were prepared for each condition, and six
random images of PM lawn were collected from each. The images were
quantified using NIH 1.62 software.
Indirect Immunofluorescence of HA-GLUT4 Translocation—An exo-
facial HA epitope-tagged GLUT4 construct containing a single HA
epitope in the first exofacial loop between transmembrane domains 1
and 2 (kindly provided by Dr. Michael Quon, National Institutes of
Health, Bethesda, MD) was inserted into the retroviral expression
vector pBabepuro and used to generate 3T3-L1 adipocytes stably ex-
pressing HA-GLUT4 as described (23). Following treatment of 3T3-L1
adipocytes stably expressing HA-GLUT4 cells were rinsed once in ice-
cold PBS and then fixed in 2% paraformaldehyde with PBS for 15 min.
Excess fixative was neutralized with 0.15 M glycine with PBS and
blocked using 1% BSA with PBS for 30 min. The coverslips were
incubated in anti-HA antibody (16B12) in 1% BSA with PBS for 1 h
followed by a fluorescein isothiocyanate-conjugated secondary antibody
in 1% BSA with PBS for 30 min. The coverslips were washed with PBS,
mounted onto glass microscope slides, and viewed as described above.
Measurement of Surface HA Labeling—3T3-L1 adipocytes expressing
HA-GLUT4 were grown in 24-well plates. Following the appropriate
treatment cells were washed twice in PBS and fixed in 2% paraform-
aldehyde with PBS for five min. The cells were blocked in 2.5% normal
swine serum with PBS for 30 min and then incubated in anti-HA
antibody (16B12 at 1:500) in 1% normal swine serum with PBS or 1%
normal swine serum with PBS alone as a control for 60 min. After
washing in 0.1% BSA with PBS (3 times for 10 min each time), the cells
were incubated with anti-mouse horseradish peroxidase conjugate (1:
5000) in 2.5% normal rat serum with PBS for 30 min. The cells were
then washed in PBS (3 3 10 min) followed by incubation in o-phe-
nylenediamine dihydrochloride reagent made up according to the man-
ufacturer’s instructions (Sigma) for 30 min in the dark. Finally, the A of
the supernatant was read at 450 nM.
Statistical Analyses—The data were normalized to the insulin re-
sponse detected in the same experiment and are expressed as percent-
ages of the average insulin effect observed. The significance of various
treatments was determined using the Student’s t test. For reasons of
clarity, statistical significance, or lack thereof, between parameters is
detailed only in situations pertinent to the discussion.
RESULTS
The Ca21 Chelator BAPTA-AM Inhibits Insulin-stimulated
Glucose Uptake—It has been suggested that extracellular Ca21
may play a role in insulin-stimulated glucose uptake in adipo-
cytes (13). Consistent with this we observed a 30% decrease in
insulin-stimulated 2-DOG uptake when cells were incubated in
Ca21 free buffer supplemented with 5 mM EGTA (Fig. 1A). To
further investigate the role of Ca21 in this process we per-
formed experiments using the membrane-permeable form of
BAPTA, namely BAPTA-AM, which is freely taken up into cells
where it is hydrolyzed by cytosolic esterases and trapped in-
tracellularly as the active chelator BAPTA. This reagent ex-
changes Ca21 more than 100 times faster than other agents
such as EGTA, because of the faster rates of association and
dissociation. Pretreatment of 3T3-L1 adipocytes with
BAPTA-AM for 10 min resulted in a dose-dependent inhibition
of insulin-stimulated 2-DOG uptake with an IC50 of 15 mM (Fig.
1B). In all further experiments we used a BAPTA-AM concen-
tration of 50 mM, at which we observed almost complete (.95%)
inhibition of insulin-stimulated 2-DOG uptake (Fig. 1C).
BAPTA-AM also caused significant inhibition of basal 2-DOG
uptake (Fig. 1C). Identical results were obtained when cells
were treated with BAPTA-AM in Ca21-free buffer (basal, 10%
6 2; BAPTA-AM, 6% 6 1; insulin, 100%; insulin 1 BAPTA-AM,
9% 6 2; n 5 4). Moreover, the nonesterified form of BAPTA or
EGTA-AM had no significant effect on basal (control, 10% 6 2;
BAPTA, 11% 6 3; EGTA-AM, 12% 6 2; n 5 3) or insulin-
stimulated 2-DOG uptake (control, 100%; BAPTA, 102% 6 5;
EGTA-AM, 97% 6 3; n 5 3). The inhibitory effect of
BAPTA-AM did not involve an effect on intracellular ATP
levels or hexokinase activity because it also inhibited insulin-
stimulated transport of the nonmetabolizable glucose analogue
3-O-methylglucose (Fig. 1D).
BAPTA-AM Inhibits GLUT4 Translocation—We next exam-
ined the effects of BAPTA-AM on GLUT4 translocation to the
cell surface using the PM lawn assay (Fig. 2). The morphology
of the plasma membrane fragments was unaffected by BAPTA-
AM. Insulin increased the level of GLUT4 at the PM by 4–5-
fold. Pretreatment with BAPTA-AM inhibited insulin-stimu-
lated GLUT4 levels in the PM lawns by ; 50%. It has
previously been reported that BAPTA-AM has no effect on
GLUT4 translocation using this assay (28). However, quanti-
tation of GLUT4 in PM lawns was not performed in that study,
in which case it is conceivable that a 50% inhibition may have
been overlooked.
To further investigate the apparent inhibition of insulin-
stimulated GLUT4 translocation by BAPTA-AM, we examined
its effects on insulin-stimulated GLUT4 translocation by sub-
cellular fractionation using differential centrifugation and im-
munoblotting (Fig. 3). In the absence of insulin very little
GLUT4 was detected in the PM fraction obtained from basal
cells. Consistent with the PM lawn data, insulin treatment
resulted in a 5-fold increase in GLUT4 levels within the PM
fraction (Fig. 3). Although BAPTA-AM alone had no significant
effect on GLUT4 translocation, it caused a significant reduction
FIG. 1. Inhibition of glucose uptake in 3T3-L1 adipocytes by
BAPTA-AM. A, 3T3-L1 adipocytes were incubated with (1) or without
(2) 1 mM insulin for 15 min in the presence (1) or the absence (2) of 1
mM extracellular Ca21 (Ext-Ca21). 2-DOG uptake was measured in the
final 2 min of treatment as described under “Experimental Procedures.”
The results depict the means 6 S.E. from four independent experi-
ments. *, p , 0.001 (insulin in the presence of extracellular Ca21
compared with insulin in the absence of extracellular Ca21). B, adipo-
cytes were incubated in the absence or the presence of increasing
concentrations of BAPTA-AM (0–50 mM) for 10 min and subsequently
treated with insulin (1 mM) for a further 15 min. 2-DOG uptake was
measured in the final 2 min of treatment. The results depict the
means 6 S.D. from two independent experiments. C, adipocytes were
incubated in the absence or the presence of BAPTA-AM (50 mM), and
basal and insulin-stimulated 2-DOG uptake was measured as described
for B. The results represent the means 6 S.E. from seven independent
experiments. *, p , 0.01 (basal compared with BAPTA-AM); **, p ,
0.001 (insulin compared with insulin and BAPTA-AM). D, adipocytes
were treated with BAPTA-AM and insulin as described for C, and basal
and insulin-stimulated 3-O-methyglucose uptake was determined as
described under “Experimental Procedures.” The results represent the
means 6 S.E. from five independent experiments. *, p , 0.001 (insulin
compared with insulin and BAPTA-AM).
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(; 50%) in insulin-stimulated GLUT4 translocation. Moreover,
insulin-stimulated translocation of the insulin responsive
aminopeptidase (IRAP), which shows virtually identical traf-
ficking properties to GLUT4 (29), was similarly inhibited by
BAPTA-AM (Fig. 3A).
BAPTA-AM Blocks Insertion of GLUT4 at the Plasma Mem-
brane—The above data suggest that although BAPTA-AM
caused almost quantitative inhibition of insulin-stimulated
glucose uptake, this reagent inhibited GLUT4 translocation by
only 50%. This discrepancy is unlikely to reflect a technical
limitation of our ability to quantify GLUT4 translocation be-
cause we observed quantitatively similar results using two
different fractionation techniques. In view of recent findings
implicating a role for Ca21 at a post-docking step in vesicle
transport (7), we reasoned that in the presence of BAPTA-AM,
GSVs may dock at the PM but be blocked in their ability to fuse
with the cell surface. Such docked vesicles may remain at-
tached to the PM during preparation of PM fractions by the
lawn technique or by subcellular fractionation, but because
they have not fused with the cell surface they may not contrib-
ute to glucose entry into the cell. To examine this possibility we
developed a surface binding assay utilizing 3T3-L1 adipocytes
expressing an exofacial tagged HA-GLUT4 construct (23). This
assay will only detect GLUT4 if it has inserted into the cell
surface lipid bilayer, thus providing an estimate of vesicle
docking and fusion. In the absence of insulin, we observed no
detectable labeling of the cell surface using the anti-HA anti-
body in cells expressing HA-GLUT4 (Fig. 4A). In insulin-
treated cells we observed a marked increase in surface labeling
of most cells in the culture (Fig. 4A). Pretreatment with
BAPTA-AM resulted in complete inhibition of insulin-stimu-
lated HA-GLUT4 translocation to the cell surface (Fig. 4A).
To obtain more quantitative data we performed further ex-
periments where the cell surface expression of HA-GLUT4 was
quantified using a colorimetric assay (Fig. 4B) (30). Consistent
with the immunofluorescence data, pretreatment with
BAPTA-AM resulted in an almost total inhibition of insulin-
stimulated cell surface expression of HA-GLUT4. These data
implicate a role for Ca21 in the fusion of GSVs with the plasma
membrane and potentially resolve the discrepancy between the
effects of BAPTA-AM on glucose transport and GLUT4 trans-
location as measured by the PM lawn technique or differential
centrifugation (Figs. 1–3).
BAPTA-AM Inhibits Insulin-stimulated Phosphorylation of
Akt—The above data implicate a role for Ca21 at two different
stages of the GLUT4 translocation process. Firstly, BAPTA-AM
was shown to inhibit the translocation of GLUT4 to the cell
surface by ;50%. Secondly, BAPTA-AM blocked the apparent
insertion of GLUT4 into the plasma membrane. Collectively,
these two effects may account for the almost complete inhibi-
tion of insulin-stimulated glucose transport by BAPTA-AM.
The first effect of BAPTA-AM may involve a limitation in the
availability of docking or fusion sites at the plasma membrane
or an additional inhibitory effect of BAPTA-AM at a step be-
tween insulin binding to its receptor and that of GLUT4 dock-
ing at the PM. Pretreatment with BAPTA-AM had no signifi-
cant effect on insulin-stimulated tyrosyl phosphorylation of the
IR and IRS-1/IRS-2 (Fig. 5, top and middle panels). In contrast,
BAPTA-AM reduced insulin-stimulated Akt phosphorylation
by 75% (Fig. 5, bottom panel). Thus, chelation of intracellular
Ca21 with BAPTA-AM results in inhibition of insulin-stimu-
lated Akt phosphorylation at a step that is distal to IR and
IRS-1/IRS-2 phosphorylation.
W13 Inhibits Insulin-stimulated Phosphorylation of Akt and
FIG. 2. BAPTA-AM inhibits the insulin-stimulated appearance
of GLUT4 in plasma membrane lawns. 3T3-L1 adipocytes grown on
glass coverslips were incubated in the absence or the presence of
BAPTA-AM (50 mM) for 10 min and subsequently treated with insulin (1
mM) for a further 15 min. Plasma membrane lawns were prepared by
mild sonication and labeled for GLUT4 as described under “Experimen-
tal Procedures.” A, images from a representative experiment. B, quan-
titation of GLUT4 staining from six independent experiments showing
the means 6 S.E. *, p , 0.001 (insulin compared with insulin and
BAPTA-AM).
FIG. 3. Insulin-stimulated GLUT4 translocation to the plasma
membrane is inhibited by BAPTA-AM. The adipocytes were incu-
bated in the absence or the presence of BAPTA-AM (50 mM) for 10 min
and subsequently treated with insulin (1 mM) for a further 15 min. The
cells were homogenized and subjected to subcellular fractionation to
generate fractions enriched in PM and the high speed pellet (HSP) that
contains intracellular GSVs. These were subjected to SDS-PAGE and
immunoblotting as described under “Experimental Procedures.” A, rep-
resentative immunoblots of GLUT4 (upper panel) and IRAP (lower
panel). B, quantitation of GLUT4 in the PM from five independent
experiments showing the means 6 S.E. *, p , 0.001 (insulin compared
with insulin and BAPTA-AM).
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Glucose Uptake—Previous studies have suggested that the
ubiquitously expressed Ca21-binding protein calmodulin is re-
quired for the efficient activation of PI 3-kinase by insulin and
subsequent activation of Akt (17). Consistent with this, we
found that pretreatment of cells with the calmodulin antago-
nist W13 inhibited insulin-stimulated Akt phosphorylation by
70% (Fig. 6A) without affecting phosphorylation of the IR and
IRS proteins (data not shown). In addition, W13 inhibited
insulin-stimulated 2-DOG uptake by 60% (Fig. 6B).
Taken together, the above data suggest that Ca21, presum-
ably via its effects on calmodulin, plays an important role in the
insulin-signaling cascade at the level of PI 3-kinase activation
and are consistent with previous reports (17). It may also be
inferred from the above data that inhibition of insulin-stimu-
lated Akt phosphorylation by either BAPTA-AM or W13 may be
at least partly responsible for the observed inhibition of GLUT4
translocation and glucose uptake. However, consistent with
previous data (31), we observed a significant discrepancy be-
tween the dose-response curves for insulin-stimulated glucose
transport and insulin-stimulated Akt phosphorylation in adi-
pocytes (Fig. 7). These data indicate that at low concentrations
of insulin (;5 nM), where glucose transport is almost at its
maximum stimulation, Akt phosphorylation is only increased
to a level that is 28% of that observed at maximum insulin
stimulation. Because BAPTA-AM or W13 only decreased Akt
phosphorylation by 70–75% at a maximum insulin concentra-
tion, it seems unlikely that this could account for the inhibitory
effects of these compounds on insulin-stimulated GLUT4 trans-
location and glucose transport.
Ionophores Prevent the Effects of BAPTA-AM on Akt Activa-
tion and GLUT4 Translocation but Not Glucose Uptake—In an
attempt to overcome the inhibitory effects of Ca21 chelation
with BAPTA-AM, we incubated cells with the Ca21 ionophores
A23187 or ionomycin. Incubation of cells with the ionophores
(or vehicle) in the absence of insulin was without effect on Akt
phosphorylation or GLUT4 translocation (data not shown). Si-
multaneous incubation of cells with either A23187 or ionomy-
cin and BAPTA-AM prevented the inhibition of insulin-stimu-
lated Akt phosphorylation by BAPTA-AM (Fig. 8A, upper
panel). Moreover, treatment with either ionophore prevented
the inhibition of insulin-stimulated GLUT4 translocation to the
FIG. 4. Inhibition of insulin-stimulated cell surface expression
of HA-GLUT4 by BAPTA-AM. 3T3-L1 adipocytes expressing HA-
GLUT4 were incubated in the absence or the presence of BAPTA-AM
(50 mM) for 10 min and subsequently treated with insulin (1 mM) for a
further 15 min. A, cells on coverslips were rinsed in PBS, and indirect
immunofluorescence was performed as described under “Experimental
Procedures.” The panels show representative images from four inde-
pendent experiments. B, cells grown in 24-well plates were rinsed twice
in PBS, and quantitation of cell surface expression of HA-GLUT4 was
determined by a colorimetric assay as described under “Experimental
Procedures.” The data represent the means 6 S.E. from four independ-
ent experiments with treatments performed in triplicate in each exper-
iment. *, p , 0.001 (insulin compared with insulin and BAPTA-AM).
FIG. 5. BAPTA-AM has no effect on insulin-stimulated IR and
IRS-1/IRS-2 phosphorylation but inhibits Akt phosphorylation.
Adipocytes were incubated in the absence or the presence of
BAPTA-AM (50 mM) for 10 min and subsequently treated with insulin (1
mM) for a further 15 min. The cells were homogenized, and subcellular
fractions were prepared and subjected to SDS-PAGE and immunoblot-
ting as described under “Experimental Procedures.” Individual panels
show representative immunoblots from five independent experiments
as follows. Top panel, pIR, antiphosphotyrosine immunoblot of the PM
fractions showing a band at ;95 kDa, which corresponds to the tyrosyl-
phosphorylated b-subunit of the IR. Middle panel, pIRS-1/2, antiphos-
photyrosine immunoblot of the high speed pellet fractions showing a
band at ;180 kDa, which corresponds to tyrosyl-phosphorylated IRS-
1/IRS-2. Bottom panel, pAkt, antiphosphospecific Akt immunoblot of
the cytosolic fractions showing a band at ;60 kDa, which corresponds
to Akt phosphorylated at Ser473. Quantitation of protein bands was
performed by densitometric analysis as described under “Experimental
Procedures.” BAPTA-AM had no significant effect on insulin-stimulated
tyrosyl phosphorylation of IR or IRS-1/IRS-2. Insulin-stimulated phos-
phorylation of Akt at Ser473 was inhibited by 75% 6 4% in the presence
of BAPTA-AM (p , 0.001).
FIG. 6. The calmodulin antagonist W13 inhibits insulin-stimu-
lated Akt phosphorylation and glucose uptake. Adipocytes were
incubated in the absence or the presence of W13 (70 mM) for 20 min and
subsequently treated with insulin (1 mM) for 15 min. A, cells were
homogenized, and subcellular fractions were prepared and subjected to
SDS-PAGE and immunoblotting as described under “Experimental Pro-
cedures.” The panel shows a representative antiphospho-Ser473 Akt
immunoblot of the cytosolic fraction. Insulin-stimulated phosphoryla-
tion of Akt was reduced by 70% 6 6% in four independent experiments
( p , 0.001). B, 2-DOG uptake was measured in the final 2 min of
treatment as described under “Experimental Procedures.” The results
depict the means 6 S.E. from four independent experiments. *, p ,
0.001 (insulin compared with insulin and W13).
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PM by BAPTA-AM, as determined by subcellular fractionation
(Fig. 8A, lower panel). Consistent with previous reports in L6
cells (9), primary adipocytes (13, 14), cardiac myocytes (12),
and isolated skeletal muscle (32) treatment with ionophores
alone was without effect on basal glucose uptake (control, 11%
6 2; A23817, 10% 6 2; ionomycin, 11% 6 2; n 5 4). However,
the ionophores did cause a slight reduction in insulin-stimu-
lated glucose uptake (control, 100%; A23817, 81% 6 5; ionomy-
cin, 82% 6 4; n 5 3). In marked contrast to the reversal of the
BAPTA-AM inhibition of Akt phosphorylation and GLUT4
translocation by ionophores, treatment with ionophores did not
reverse the inhibitory effects of BAPTA-AM on insulin-stimu-
lated 2-DOG uptake (Fig. 8B).
BAPTA-AM Inhibits GLUT4 and GLUT1 Transporter Activ-
ity—The inability of ionophores to overcome the inhibitory
effects of BAPTA-AM on insulin-stimulated glucose transport
may be due to a direct effect of BAPTA-AM on the activity of the
GLUT4 transporter. To investigate this possibility cells were
treated with insulin at 37 °C for 15 min to stimulate translo-
cation of GLUT4 to the cell surface. The cells were then rapidly
cooled to 4 °C by washing in ice-cold buffer and maintained on
ice to prevent further vesicular trafficking. The cells were then
treated with BAPTA-AM for increasing times, and 2-DOG up-
take was measured at 4 °C. As illustrated in Fig. 9A, the effects
of insulin treatment prior to temperature shift were consistent
with those seen earlier (Fig. 1), with insulin stimulating 2-DOG
uptake 10-fold. Treatment of cells with BAPTA-AM resulted in
a time-dependent inhibition of 2-DOG uptake. This inhibition
was noticeable even at the earliest time point studied (0 min),
where BAPTA-AM was added simultaneously with the 2-DOG.
To test the specificity of the effects of BAPTA-AM at 4 °C, we
performed similar experiments using the calmodulin antago-
nist W13 and the nonesterified membrane impermeant BAPTA
or EGTA-AM (Fig. 9B). Consistent with the results above, 10
min of treatment with BAPTA-AM at 4 °C resulted in an ap-
proximately 35% reduction in maximal 2-DOG uptake (Fig.
9B). In contrast, W13, BAPTA, or EGTA-AM had no significant
effect on glucose transport. These data indicate that
BAPTA-AM may inhibit the activity of GLUT4 even when its
presence at the PM is maintained by inhibiting endocytosis,
under conditions that are independent of insulin-signaling or
GLUT4 translocation. Moreover, the inhibition of GLUT4
transporter activity is specific to BAPTA-AM and appears to
require access to the interior of the cell.
To determine whether the inhibition of glucose transporter
activity by BAPTA-AM was specific to GLUT4, we investigated
the effects of BAPTA-AM in CHO cells. These cells express high
levels of the GLUT1 glucose transporter, but they do not ex-
press GLUT4 (33). In CHO.IR cells insulin stimulated 2-DOG
uptake by almost 2-fold (Fig. 10A), and both basal and insulin-
stimulated 2-DOG uptake were dramatically inhibited by pre-
treatment with BAPTA-AM (Fig. 10A). Following insulin treat-
ment and rapid cooling of cells to 4 °C, as described above,
incubation with BAPTA-AM for 10 min resulted in a 30%
reduction in maximal 2-DOG uptake, whereas treatment with
BAPTA or EGTA-AM was without significant effect (Fig. 10B).
These results are comparable with those observed in 3T3-L1
adipocytes, suggesting that the inhibition of GLUT4 and
GLUT1 transporter activity by BAPTA-AM occurs in a similar
fashion. Ionophores were unable to overcome the inhibition of
2-DOG uptake by BAPTA-AM in either 3T3-L1 cells or CHO.IR
cells at 4 °C (data not shown).
DISCUSSION
In the current study we have investigated the role of Ca21 in
insulin-stimulated glucose uptake in 3T3-L1 adipocytes. By
chelating intracellular Ca21 with BAPTA-AM or inhibiting cal-
modulin with W13, we find that Ca21/calmodulin is required at
two stages of insulin-stimulated glucose uptake. Firstly, Ca21/
calmodulin is involved in the translocation process that trig-
FIG. 8. Ionophores prevent the inhibition of insulin-stimu-
lated Akt phosphorylation and GLUT4 translocation, but not
glucose uptake, by BAPTA-AM. Adipocytes were incubated in the
absence or the presence of BAPTA-AM (50 mM) and A23187 (lane A, 0.1
mM) or ionomycin (lane I, 0.1 mM) for 10 min and subsequently treated
with insulin (1 mM) for a further 15 min. A, cells were homogenized, and
subcellular fractions were prepared and subjected to SDS-PAGE and
immunoblotting as described under “Experimental Procedures.” Upper
panel, pAkt, representative antiphospho-Ser473 Akt immunoblot of the
cytosolic fractions. Lower panel, GLUT4, representative immunoblot of
GLUT4 in the PM fractions. B, measurements of 2-DOG uptake for 2
min from four independent experiments performed as described under
“Experimental Procedures.” The data are the means 6 S.E.
FIG. 7. Dose response of insulin-stimulated Akt phosphoryla-
tion and 2-DOG uptake in 3T3-L1 cells. 3T3-L1 adipocytes were
incubated in the absence or the presence of increasing concentrations of
insulin for 15 min. A, cells were homogenized, and subcellular fractions
were prepared and subjected to SDS-PAGE and immunoblotting as
described under “Experimental Procedures.” The panel shows a repre-
sentative antiphospho-Ser473 Akt immunoblot of the cytosolic fraction
from cells treated with 0, 1, 5, 10, 100, and 1000 nM insulin. Quantita-
tion of Akt phosphorylation (f) and 2-DOG uptake (M) from four sep-
arate experiments is shown in B. 2-DOG uptake was measured in the
final 2 min of treatment as described under “Experimental Procedures.”
The data are the means 6 S.E.
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gers the exocytosis of intracellular GLUT4-containing vesicles.
This may involve the insulin signaling pathway, because we
observed a significant decrease in Akt activation in response to
BAPTA-AM or W13. Secondly, there is a requirement for Ca21
at a post-docking stage of GLUT4 vesicle translocation to the
PM, presumably involving membrane fusion. In addition to the
above findings we also present evidence that BAPTA-AM in-
hibits the activity of mammalian facilitative glucose transport-
ers (GLUT1 and GLUT4) independently of Ca21, possibly by
binding to the glucose-binding site in the transporter.
In the present report we have made three separate observa-
tions supporting a role for Ca21/calmodulin in insulin-stimulated
glucose transport. First, exclusion of Ca21 from the extracellular
buffer resulted in a 30% decrease in insulin-stimulated glucose
uptake. Second, the Ca21 chelator BAPTA-AM inhibited insulin-
stimulated GLUT4 translocation and the fusion of GLUT4 vesi-
cles with the plasma membrane. Third, the calmodulin antago-
nist W13 inhibited insulin-stimulated glucose uptake by 60%. A
number of other studies have also suggested a role for Ca21 in
insulin-stimulated glucose transport. Incubation of adipocytes
with ionomycin in the absence of extracellular Ca21 or with the
Ca21 chelator Quin 2-AM inhibited insulin-stimulated glucose
transport (13–15). There is also accumulating evidence to impli-
cate calmodulin in this process. The calmodulin antagonist CGS
9343B and the Ca21-dependent calmodulin protein kinase II
inhibitor KN 62 reduced insulin-stimulated glucose uptake in rat
skeletal muscle (34, 35). In contrast a number of studies have
failed to find a role for Ca21 in insulin-stimulated glucose uptake
(9–12, 36). For example, removal of extracellular Ca21 or chela-
tion of intracellular Ca21 using fura-2 had no effect on basal or
insulin-stimulated glucose transport in cardiac myocytes (12).
One possibility for this controversy may be that many of the
agents that are used to chelate intracellular Ca21 do so with a
large variation in efficiency because of differences in associa-
tion/dissociation constants for Ca21 (12, 37). For example,
BAPTA has .100-fold higher association and dissociation rates
than EGTA (37). A second problem is that many of the tech-
niques used to chelate Ca21 may not have accessed all of the
intracellular pools of Ca21. It has recently been shown that
Ca21 plays an important role in vesicle fusion and that the
Ca21 is released from the lumen of the vesicle during the actual
fusion process (18–20, 37). Hence, in this instance it is neces-
sary to use fast chelators such as BAPTA or chelators that can
cross all lipid membranes. A third factor is the use of reagents
at suboptimal concentrations and cell models with limited re-
sponses (see Ref. 14 for a discussion).
One of the steps in the insulin-stimulated accumulation of
GLUT4 at the cell surface that requires Ca21 is the actual
translocation process itself. In view of the complex nature of
this process, we have been unable to pinpoint the precise locus
of the Ca21-dependent step. However, it may involve the insu-
lin signal transduction pathway because we observed a signif-
icant decrease in insulin-stimulated Akt phosphorylation in
the presence of either BAPTA-AM or W13. This appeared to be
a specific effect because upstream signaling events including
FIG. 9. Inhibition of GLUT4 transporter activity by BAPTA-AM
but not W13, BAPTA, or EGTA-AM at 4 °C. A, adipocytes were
incubated in the absence or the presence of insulin (1 mM) for 15 min at
37 °C. The cells were then rapidly cooled to 4 °C by washing in ice-cold
buffer and incubating on ice. BAPTA-AM (50 mM) was added at the
appropriate time, and 2-DOG uptake was measured for 1 min as de-
scribed under “Experimental Procedures.” It is noteworthy that all cells
were incubated at 4 °C for the same duration. The data depict the
means 6 S.D. from two independent experiments. B, adipocytes were
incubated with insulin (1 mM) for 15 min at 37 °C and then cooled to 4 °C
as described above. The cells were incubated for a further 10 min in the
absence or the presence of BAPTA-AM (B-AM), W13, BAPTA (B), or
EGTA-AM (E-AM) (all at 50 mM except W13, which was at 70 mM), and
2-DOG uptake was measured for 1 min as described under “Experimen-
tal Procedures.” The data depict the means 6 S.E. of four independent
experiments. *, p , 0.001 (absence compared with presence of
BAPTA-AM).
FIG. 10. Inhibition of GLUT1 transporter activity by
BAPTA-AM but not BAPTA or EGTA-AM at 4 °C. A, CHO.IR cells
grown in 12-well plates were incubated in the absence or the presence
of BAPTA-AM (50 mM) for 10 min and subsequently treated with insulin
(1 mM) for a further 15 min. 2-DOG uptake was measured for 2-min as
described under “Experimental Procedures.” The data represent the
means 6 S.E. from four independent experiments. *, p , 0.001 (basal
compared with BAPTA-AM); **, p , 0.001 (insulin compared with
insulin and BAPTA-AM). B, CHO.IR cells were incubated in the pres-
ence of insulin (1 mM) for 15 min and then cooled rapidly to 4 °C by
washing in ice-cold buffer and incubating on ice. The cells were incu-
bated for a further 10 min in the absence or the presence of BAPTA-AM
(B-AM), BAPTA (B), or EGTA-AM (E-AM) (all at 50 mM), and 2-DOG
uptake was measured for 1 min as described under “Experimental
Procedures.” The data represent the means 6 S.E. from four independ-
ent experiments. *, p , 0.001 (absence compared with presence of
BAPTA-AM).
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IR and IRS-1/2 phosphorylation were intact. However, further
scrutiny of this step makes it unlikely that this is the sole cause
of the defect in GLUT4 translocation. The dose-response curves
of Akt phosphorylation and glucose uptake are significantly
different, and the inhibition of insulin-stimulated Akt phospho-
rylation observed with either BAPTA-AM or W13 was only
partial. One possibility is that a specific intracellular pool of
Akt may be more potently inhibited by BAPTA-AM or W13.
However, we were unable to find any evidence for this by
measuring Akt phosphorylation in different subcellular frac-
tions. Nevertheless, these data clearly implicate an important
role for Ca21/calmodulin in the full activation of Akt, and this
is likely to be relevant to other downstream events. This is
consistent with previous reports showing that activation of PI
3-kinase by insulin is inhibited by calmodulin antagonists (17)
or by inhibition of Ca21 influx (16). Direct interactions between
calmodulin and IRS-1 and also between calmodulin and PI
3-kinase provide a potential explanation for the above effects
(38, 39).
The inhibition of GLUT4 translocation by BAPTA-AM ac-
counted for a 50% loss in GLUT4 at the PM, as determined by
either the PM lawn assay or subcellular fractionation. How-
ever, the insulin-stimulated appearance of GLUT4 at the cell
surface, as determined by cell surface binding, was totally
blocked. Taken together, these data highlight the potential
unsuitability of subcellular fractionation and plasma mem-
brane lawns to unambiguously detect GLUT4 insertion at the
plasma membrane. We surmise that the GLUT4 vesicles are
docked at the PM but are unable to subsequently fuse and
integrate into the cell surface membrane. It is known that
docking complexes, involving the SNARE proteins, when
formed do so with very high affinity (40). It is therefore likely
that docked vesicles would remain attached to the PM during
isolation of these membranes in vitro.2 This conclusion is sup-
ported by recent findings from in vitro vesicle fusion reactions
where it has been shown that BAPTA, but not EGTA, inhibits
endosome-endosome (37), endosome-lysosome (20), intra-Golgi
membrane (19), and vacuole membrane fusion at a post-dock-
ing step (18). Similarly, calmodulin antagonists inhibited ves-
icle fusion, and this effect was reversed by the addition of
excess calmodulin (18, 19). Hence, there is now considerable
evidence to suggest a potential role for Ca21/calmodulin in
many different, if not all, vesicle fusion events in eukaryotic
cells. Therefore the fusion of GLUT4 vesicles with the PM
would appear to represent another example of Ca21/calmodu-
lin-regulated fusion.
In the current study we have not specifically addressed
whether insulin regulates intracellular Ca21 levels. However,
our data may contribute to the ongoing discussion related to this
question. Several studies failed to detect an insulin-dependent
change in intracellular Ca21 in various cell types including cul-
tured myotubes, cardiac myocytes, and adipocytes (9–12). In
contrast, using the fluorescent Ca21 indicators Indo-1 and FIP18,
it has recently been shown that in intact single skeletal muscle
fibers near membrane, but not global, Ca21 concentrations are
increased in response to insulin (41). Moreover, L-type Ca21
channel blockers, which have previously been shown to inhibit
insulin-stimulated glucose transport (42), prevented this re-
sponse (41). Our studies are consistent with this because we
observed a modest decrease in insulin-stimulated glucose trans-
port upon removal of extracellular Ca21. In addition, the GLUT4
vesicles themselves may contribute to the near membrane in-
crease in Ca21. In the case of endosome-endosome (37), endo-
some-lysosome (20), intra-Golgi membrane (19), and vacuole
membrane fusion (18), it has been concluded that Ca21 is re-
leased from the lumen of the vesicles, thus promoting fusion. This
conclusion was based on the observation that vesicle fusion was
inhibited in the presence of EGTA-AM but not EGTA (20, 37). In
contrast, the nonesterified version of BAPTA was able to inhibit
fusion, presumably because of its fast Ca21 exchange rate (18–
20, 37). However, in these studies it was necessary to use very
high concentrations of EGTA-AM, probably because of the very
high intralumenal Ca21 levels in these organelles. By analogy we
surmise that GLUT4 vesicles may also contain Ca21 that is
released into the cytoplasm when the vesicles are docked at the
PM. These findings may explain a number of previous observa-
tions concerning the role of Ca21 in insulin action. Firstly, they
may explain why elevated Ca21 alone is not capable of triggering
GLUT4 translocation. The elevation in Ca21 may only be in-
volved at a late stage when the vesicles have docked with the
membrane. Secondly, they may explain the difficulty in overcom-
ing these effects with ionophores. A burst in the release of in-
tralumenal vesicular Ca21 triggers this event rather than a
global increase in intracellular Ca21. Thirdly, they may explain
why slow Ca21 chelators such as EGTA fail to inhibit this process
and emphasizes the utility of the fast Ca21 chelator BAPTA. We
have previously shown that in streptolysin O-permeabilized adi-
pocytes insulin-stimulated GLUT4 translocation is preserved in
the presence of EGTA (27). However, this slow Ca21 chelator
would not have accessed the lumen of the GLUT4 vesicles, thus
potentially explaining the inability of this reagent to inhibit
GLUT4 translocation. Finally, we have been unable to recapitu-
late the effects of BAPTA-AM using EGTA-AM. It is possible that
there may be difficulty in reaching concentrations high enough to
chelate the intralumenal calcium levels inside these vesicles.
Additionally, the hydrolyzing esterases may not be present in the
lumen of these vesicles.
In the present study we were able to reverse the BAPTA-AM
inhibition of insulin-stimulated Akt phosphorylation and
GLUT4 translocation with ionophores. However, this was
not the case for glucose transport. Our observation that
BAPTA-AM inhibited basal glucose transport was also of note.
Three additional observations suggest that this effect may rep-
resent a separate, Ca21-independent, effect of BAPTA-AM to
inhibit the transport activity of the transporter itself. First,
glucose transport was sensitive to BAPTA-AM at 4 °C. Second,
glucose transport in CHO.IR cells was inhibited by BAPTA-
AM. These effects were unaltered by ionophores. Third, molec-
ular modeling studies indicate that many low energy confor-
mations of BAPTA are capable of presenting a glucose-type
arrangement of oxygen atoms (data not shown). This effect is
similar to that described for the glucose transport inhibitor
cytochalasin B, which is a rigid macrocycle (43). Because of the
above, we propose that in aqueous buffers BAPTA is able to
assume a conformation that resembles the D-isomer of glucose,
which may therefore allow it to act as a competitor of glucose
binding. This may make this reagent less suitable for in vivo
experiments than previously realized.
In conclusion, we suggest that Ca21/calmodulin does play an
important role in insulin action on glucose transport. First it is
involved in some aspect of the GLUT4 translocation process,
and second it is involved in the fusion of GLUT4 vesicles with
the PM. Based on recent studies it is tempting to speculate that
the molecular regulation of both of these processes may be
linked, possibly at the PM. Klip and co-workers have recently
shown that key elements of the insulin signal transduction
pathway including PI 3-kinase assemble at unique sites at the
PM (44). Importantly, they have also shown that GLUT4 ves-
2 It is conceivable that docked GLUT4 vesicles may dissociate from
the PM during subcellular fractionation. Therefore it remains possible
that the apparent insulin-stimulated translocation of GLUT4 in the
presence of BAPTA-AM may be an underestimate.
Ca21 and Insulin Action 27823
 at UQ Library on October 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
icles appear to insert at these same sites. It will therefore be of
interest to determine whether calmodulin, which has been
reported to interact with PI 3-kinase (39), is also concentrated
at such sites and whether BAPTA-AM or other relevant inhib-
itors can prevent the assembly of these structures.
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